Jupiter Neurosciences, Inc. (NASDAQ: JUNS) announced it has entered into a securities purchase agreement for a registered direct offering of 307,692 shares of common stock, with gross proceeds of approximately $2.0 million, according to a company press release.

D. Boral Capital LLC is acting as the exclusive placement agent for the offering. The closing is expected to occur on or about August 24, 2026, subject to customary closing conditions.

The shares are being offered pursuant to an effective shelf registration statement on Form S-3 (Registration No. 333-295085), which was declared effective by the U.S. Securities and Exchange Commission on April 24, 2026.

Jupiter Neurosciences is a clinical-stage biopharmaceutical company focused on central nervous system disorders and neuroinflammation.